DE EN Anmelden

In your studies 'Drug Regulator Affairs'

©Volker Lannert / Universität Bonn

Master's thesis


As part of the continuing education Master's degree programme, Master's theses are written on relevant topics in the field of 'Drug Regulatory Affairs' using scientific methods. The topics are highly topical, diverse and the results are both of interest in a scientific context and relevant to many areas of activity in 'Drug Regulatory Affairs'.

Here you will find all Master's theses written since the year 2000, including the title and a summary. In this collection, many Master's theses can also be viewed and downloaded in full text.

Further information on Master's theses (e.g. registration, processing) can be found in our ‘Master's thesis guidelines/Leitfaden für die Anfertigung einer Masterarbeit’ (in German) and in the ‘Information leaflet - Master's thesis’ at

Downloads from A-Z

Do you have any questions or are you interested in the full text of a Master's thesis that is not listed here?
Please feel free to contact me.

Dr. Jasmin Fahnenstich

Dr. Jasmin Fahnenstich

Study programme manager

Phone: +49 (0) 228 - 9268 6806

Send e-mail

Master's thesis

The collection of Master's theses can be searched and sorted by entering keywords.

Year Name Title Full text Summary
2014 Dr. Anke Webler-Messenger The Company Core Data Sheet: From CIOMS to the implications of the new Pharmacovigilance Legislation ***
2014 Britta Weingarten Current drug safety measures for thalidomide and their national implementation in Germany and the UK ***
2014 Frauke Wellhausen Challenges in the regulatory requirements for homeopathic medicinal products in Canada and the European Union with Germany and Belgium as examples under special consideration of recent developments ***
2014 Dr. Susanne Weyel-Schnurrer Comparative Presentation of the Procedure of Active Substance Master File & Certificate of Suitability and the Implication on the Marketing Authorisation Dossier ***
2014 Dr. Uta Wrackmeyer The process of implementing Directive 2010/63/EU into German law
2014 Jing Yuan Comparison of Medical Devices Regulations in the EU and the People's Republic of China-Current situation and possible implications of the new Chinese Medical Device Guideline (2014)
2014 Dr. Yuan Zhao The regulatory process of electronic submission and its optimization
2013 Dr. Heidrun Albrecht Experiences with PIPs and their required revisions on the critical path of the development of medicines in indications for adult patients ***
2013 Dr. Fatima Bicane Abuse Deterrent Formulation: The new approach to reduce prescription drug abuse in the United States ***
2013 Clelia Bonadei Obligations of economic operators, traceability, vigilance and market surveillance of medical devices as foreseen by the EU Commission Proposal for a Regulation on Medical Devices of 26 Sept. 2012: comparison with existing requirements and evaluation ***
2013 Dr. Carmen Boxler "Compassionate Use", its practical implications and comparison of the regulatory framework of France, Spain, Germany and the United Kingdom
2013 Dr. Annika Brendle Mechanisms of carcinogenesis and their role in anti-cancer drug approvals via the EU centralised procedure (1995–2009) ***
2013 Dr. Sarah Burrack Status, challenges and regulatory strategies to develop a malaria vaccine ***
2013 Claudia Callies-Klüpfel The new European Health Claims Regulation establishing a List of permitted Health Claims: Questions around its Application and the current State of Discussion to the “Claims on Hold” and to the “Botanicals” as well as a comparative
2013 Alex Dranov European View on Current Regulatory Legislation in the CIS Countries. Marketing Authorisation of Herbal Medicinal Products in Russia and the Ukraine ***
2013 Inga Kristin Drosse Antibiotics in veterinary medicine - A European Regulatory Perspective ***
2013 Berit Fasse Acceptability of brand names for human medicinal products. With focus on German non-generic OTC umbrella brand discussion
2013 Dr. Thomas Flötotto Classification of Antiseptics and Disinfectants for Human use. The Demarcation between Biocides, Medicinal Products, Medical Devices and Cosmetics ***
2013 Karsten Gavenis Conducting Clinical Trials in Orthopedic Indications in Germany
2013 Mecit Gedik Verbesserung der Arzneimittelsicherheit durch Aufnahme in das BtM-Gesetz am Beispiel des Tilidins ***
  • Total: 720